Thirty percent of kidney transplant recipients are readmitted in the first month posttransplantation. Those with donor-specific antibody requiring desensitization and incompatible live donor kidney transplantation (ILDKT) constitute a unique subpopulation that might be at higher readmission risk. Drawing on a 22-center cohort, 379
ILDKTs with Medicare primary insurance were matched to compatible transplantmatched controls and to waitlist-only matched controls on panel reactive antibody, age, blood group, renal replacement time, prior kidney transplantation, race, gender, diabetes, and transplant date/waitlisting date. Readmission risk was determined using multilevel, mixed-effects Poisson regression. In the first month, ILDKTs had a 1.28-fold higher readmission risk than compatible controls (95% confidence interval [CI] 1.13-1.46; P < .001). Risk peaked at 6-12 months (relative risk [RR] 1.67, 95% CI 1.49-1.87; P < .001), attenuating by 24-36 months (RR 1.24, 95% CI 1.10-1.40; P < .001).
ILDKTs had a 5.86-fold higher readmission risk (95% CI 4.96-6.92; P < .001) in the first month compared to waitlist-only controls. At 12-24 (RR 0.85, 95% CI 0.77-0.95; P = .002) and 24-36 months (RR 0.74, 95% CI 0.66-0.84; P < .001), ILDKTs had a lower risk than waitlist-only controls. These findings of ILDKTs having a higher readmission risk than compatible controls, but a lower readmission risk after the first year than waitlist-only controls should be considered in regulatory/payment schemas and planning clinical care.
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| INTRODUCTION
In an effort to reduce healthcare expenditures, the Affordable Care Act mandates that the Centers for Medicare & Medicaid Services (CMS) reduce payments to hospitals with excess readmissions.
1 Significant legislative and lobbying efforts have been made to exempt transplants from these penalties, as transplant recipients are a population at high risk of readmission. [2] [3] [4] Indeed, approximately 30% of kidney transplant recipients will be readmitted in the first month following discharge after the transplantation. 5 When considering readmission risk, one might worry in particular about recipients with donor-specific antibody (DSA) requiring desensitization and subsequent incompatible live donor kidney transplantation (ILDKT). Desensitization increases the magnitude of immunosuppression early after transplantation (plasmapheresis), and this effect may extend beyond the first month (anti-CD20), possibly increasing the incidence of posttransplantation infections requiring readmission, although the data are conflicting. [6] [7] [8] DSA certainly places these patients at higher risk of rejection, and up to half of such patients will develop antibody-mediated rejection in the first year posttransplantation, also likely requiring readmission. 9 In addition, sensitized patients have longer transplant waiting times and years of renal replacement, which would be predicted to result in a greater burden of comorbidity and higher rates of readmission related to these comorbid conditions.
Although understanding and quantifying readmission risk in this population would be critically important for both patient care planning as well as regulatory policy, no data currently exist.
We hypothesized that ILDKT recipients would be at higher risk for readmission than the general compatible live donor kidney transplant population and at lower risk than patients remaining on the kidney transplant waitlist. The former comparison is important within the current regulatory framework that judges transplant center outcomes without accounting for the distinctions between compatible and ILDKT recipients. The latter comparison is important from a hospitallevel and larger healthcare policy point of view. We linked data from a 22-center study of ILDKT recipients, 10, 11 and from the national dialysis registry, to Medicare claims data to ascertain readmission.
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| METHODS
| Study population
The study population was drawn from a 22-center cohort of patients known to be ILDKT recipients and has been described previously. 
| Transplant waitlist-only matched controls
The waitlist-only matched controls were drawn from a pool of active 90 831 unique kidney transplant candidate registrants with Medicare insurance at least 60 days prior to their waitlist date.
| Matching algorithm
Matching was performed using a previously described iterative expanding radius matching algorithm, 
| Readmissions
Readmission was defined as admission to any acute care hospital, based on Medicare claims, after discharge from the index kidney transplant hospitalization. For transplant waitlist-only matched controls, "readmission" was considered as any hospitalization to an acute care hospital that occurred from the day of matching to an ILDKT recipient onward. In a separate analysis, readmission rates of ILDKT recipients who died were compared to their matched controls, as were readmission rates of ILDKT recipients who experienced graft loss.
| Primary diagnosis for readmission
The primary diagnosis, as recorded using the International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code in the USRDS for each readmission was tallied for each patient group and across prespecified time periods.
| Statistical analysis
Between-group characteristics were compared using Pearson's chisquare test for categorical variables and Somers' D rank statistics test for continuous variables to account for clustering. [22] [23] [24] The incidence of readmission at various time points was determined within the first 
| RESULTS
| Study population
The 379 eligible ILDKT recipients from 18 centers were matched to 1895 compatible kidney transplant recipients and 1895
waitlist-only recipients. There was no statistically significant difference in age between ILDKT recipients and compatible transplantmatched controls (43.8 vs 44.9; P = .14), although waitlist-only matched controls were slightly older than ILDKT recipients (46.0; P = .003) ( 
| Readmission incidence and cumulative incidence
Within the first month of discharge from the hospital after kidney transplant, ILDKT recipients had an incidence of hospital readmission of 29.3 per 1000 patient days, compared to 22.9 and 5.0 for compatible transplant-matched controls and transplant waitlist-only matched controls ( Figure 1) . From 1-6 months, the incidence of hospital readmission for ILDKT, compatible transplant-matched controls, and waitlist-only matched controls was 9.0, 6.0, and 4.8 readmissions per 1000 patient days, respectively. From 6-12 months, the incidence was 5.8, 3.5, and 4.8 readmissions per 1000 patient days, respectively. From 12-24 months, the incidence was 3.9, 2.9, and 4.5 readmissions per 1000 patient days, respectively. From 24-36 months, the incidence of hospital readmission was 3.1, 2.5, and 4.1 readmissions per 1000 patient days, respec- transplant-matched controls, and 2.8%, 3.5%, 3.5%, 3.5%, and 3.2% for waitlist-only matched controls (Table 3 ).
| Relative risk of readmission vs compatible transplant-matched controls
For the entire duration of follow-up, the relative risk (RR) of readmission for ILDKT recipients was higher than for compatible transplantmatched controls: 0-1 month (RR 1.28, 95% CI 1.13-1.46; P < .001), Figure 2) . A sensitivity analysis comparing the RR of readmission of ILDKT recipients and compatible transplant-matched controls after controlling for the statistically significantly different variables in Table 1 showed point estimates, CIs, and P-values that were virtually identical (data not shown).
| Relative risk of readmission vs waitlist-only matched controls
From 0-1 month, ILDKT recipients had a 5.86-fold (95% CI 4.96-6.92; P < .001) higher risk of readmission than waitlist-only matched controls (Table 4 ; Figure 3) . From 1-6 months, ILDKT recipients had a 1.89-fold (95% CI 1.69-2.10; P < .001) higher risk, and from 6-12 months, the risk was 1.22-fold higher (95% CI 1.09-1.36; P < .001). However, after the first year, the RR of readmission was lower for ILDKT recipients than for waitlist-only matched controls. Table 1 showed point estimates, CIs, and P-values that were virtually identical (data not shown).
| Primary diagnosis for readmissions
At all time points and across all three groups, the most common primary diagnosis for readmission was "Complications peculiar to specific conditions" ( Figure S1 ). Following that, in the first month, 9.2%, 5.0%, and 3.7% of ILDKT readmissions were for procedural complications, fluid electrolyte/acid-base disorders, and urethra/urinary tract disor- of waitlist-only matched control readmissions for septicemia, heart failure, and hypertensive chronic kidney disease.
| Readmission rates of ILDKT recipients who died compared to matched controls
During the study period, 122 ILDKT recipients died. In the first month, 1-6 months, 6-12 months, 12-24 months, and 24-36 months, the readmission rate per 1 person-year among the ILDKT recipients who died was 13.2, 5.1, 3.9, 2.5, and 1.6, compared to 8.3 (P < .001), 2.2 (P < .001), 1.4 (P < .001), 0.9 (P < .001), and 1.1 (P < .001) for their compatible transplant-matched controls, and 2.2 (P < .001), 2.1 (P < .001), 2.1 (P < .001), 1.9 (P < .001), and 1.8 (P = .
2) for their waitlist-only matched controls.
| Readmission rates of ILDKT recipients with graft loss compared to matched controls
During the study period, 134 ILDKT recipients experienced deathcensored graft loss. In the first month, 1-6 months, 6-12 months, 12-24 months, and 24-36 months, the readmission rate per 1 person-year among the ILDKT recipients who experienced graft loss was 11.6, 3.7, 2.7, 1.8, and 1.9, compared to 8.3 (P = .002), 2.2 (P < .001), 1.3 (P < .001), 1.1 (P < .001), and 0.9 (P < .001) for their compatible transplantmatched controls, and 2.0 (P < .001), 1.9 (P < .001), 1.9 (P < .001), 1.8 (P = .7), and 1.7 (P = .1) for their waitlist-only matched controls.
| Predictors of readmission among ILDKT recipients
Black race (incidence rate ratio 
| DISCUSSION
In this 22-center study, ILDKT was associated with a higher risk of hospital readmission than compatible transplant-matched controls, a finding that held true even 3 years posttransplantation. In the first month after discharge, ILDKT recipients had a 1.28-fold higher risk of readmission than compatible kidney transplant recipients; the risk peaked at 1.67-fold higher during the 6-12 month period post-index hospitalization discharge and then decreased to 1. metrics frequently reported publicly and used to determine reimbursements. ILDKT recipients in our study had a consistently higher risk of readmission than compatible transplant-matched controls; this reality of desensitization may serve as a disincentive for transplant centers to undertake ILDKT, even in light of the substantial survival benefit seen with this treatment modality. 11, 17 This only worsens the existing disincentive to care for these patients given a higher likelihood of flagging by CMS for further regulatory scrutiny.
15
Understanding readmission patterns is particularly important given the increased cost associated with ILDKT. We recently reported that ILDKT is associated with a 41% increase in cost compared to compatible live donor kidney transplantation ($151,024 vs $106,636; P < .001), highlighting the importance of paired kidney exchange. However, even under optimal circumstances, less than half of patients will find a compatible donor, 26 and many of the ensuing matches are not compatible, but rather, less incompatible. Vo and colleagues reported that compared to dialysis, desensitization with rituximab and intravenous Ig was associated with nearly $19 000 in savings by 3 years posttransplantation. More recent kidney allocation system changes have given priority to sensitized patients on a sliding scale, leading to a bolus effect in which patients with PRA 98-100
have become more likely to get transplanted at the expense of sensitized patients with lower PRA values. 27 Although the long-term effects of these policy changes remain to be seen, these allocation system changes and kidney paired exchange may obviate the need for desensitization for some patients and reduce time on and cost of dialysis, but certainly not for all patients. Desensitization, including in combination with paired kidney exchange, is likely to remain a major treatment modality for difficult-to-match patients.
Limitations include the restriction to Medicare beneficiaries, which was necessary for outcome ascertainment but reduced sample size and may somewhat limit generalizability. However, this is, to our knowledge, the largest study of readmissions in this challenging patient population, and our findings were statistically significant, indicating that we had a sufficient sample size to ask the questions we were asking.
In addition, there may be some residual confounding, particularly as some significant differences remained between the groups even after matching. However, most of those differences, although statistically significant, were not clinically meaningful. Although we could identify the primary diagnosis codes for the readmissions, the data are limited in their granularity. Further study will be needed to understand better why these patients require readmission to the hospital.
In conclusion, ILDKT is perpetually associated with an increased 
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